214 related articles for article (PubMed ID: 34727329)
21. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
[TBL] [Abstract][Full Text] [Related]
22. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
[TBL] [Abstract][Full Text] [Related]
24. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
[TBL] [Abstract][Full Text] [Related]
25. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
Sacchi S; Vinci G; Gugliotta L; Rupoli S; Gargantini L; Martinelli V; Baravelli S; Lazzarino M; Finazzi G
Haematologica; 2000 May; 85(5):492-5. PubMed ID: 10800165
[TBL] [Abstract][Full Text] [Related]
27. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
28. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
[TBL] [Abstract][Full Text] [Related]
29. Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A; Wassie EA; Lasho TL; Finke C; Belachew AA; Ketterling RP; Hanson CA; Pardanani A; Gangat N; Wolanskyj AP
Leukemia; 2014 Dec; 28(12):2300-3. PubMed ID: 24791854
[TBL] [Abstract][Full Text] [Related]
30. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
31. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F; Thiele J; Girodon F; Rumi E; Carobbio A; Gisslinger H; Kvasnicka HM; Ruggeri M; Randi ML; Gangat N; Vannucchi AM; Gianatti A; Gisslinger B; Müllauer L; Rodeghiero F; d'Amore ES; Bertozzi I; Hanson CA; Boveri E; Marino F; Maffioli M; Caramazza D; Antonioli E; Carrai V; Buxhofer-Ausch V; Pascutto C; Cazzola M; Barbui T; Tefferi A
Blood; 2012 Aug; 120(6):1197-201. PubMed ID: 22740446
[TBL] [Abstract][Full Text] [Related]
32. What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia.
Kuykendall AT; Komrokji R
J Natl Compr Canc Netw; 2020 Sep; 18(9):1279-1284. PubMed ID: 32886905
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.
Chiatamone Ranieri S; Arleo MA; Trasarti S; Bizzoni L; Carmosino I; De Luca ML; Mohamed S; Mariggiò E; Scalzulli E; Rosati S; De Benedittis D; Colafigli G; Pepe S; Molica M; Scamuffa MC; Di Prima A; Ferretti A; Baldacci E; Mancini M; Santoro C; Vignetti M; Breccia M; Latagliata R
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e328-e333. PubMed ID: 33342728
[TBL] [Abstract][Full Text] [Related]
35. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
36. [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
Melikyan AL; Subortseva IN; Sudarikov AB; Kovrigina AM; Gilyazitdinova EA; Kolosheinova TI; Abdullaev AO; Treglazova SA
Ter Arkh; 2017; 89(7):4-9. PubMed ID: 28766534
[TBL] [Abstract][Full Text] [Related]
37. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A; Latagliata R; Anaclerico B; Spadea A; Rago A; Di Veroli A; Spirito F; Porrini R; De Muro M; Crescenzi Leonetti S; Villivà N; De Gregoris C; Montefusco E; Polverelli N; Santoro C; Breccia M; Cimino G; Majolino I; Mazzucconi MG; Vianelli N; Alimena G; Montanaro M; Palandri F
Am J Hematol; 2016 Mar; 91(3):318-21. PubMed ID: 26748894
[TBL] [Abstract][Full Text] [Related]
38. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
39. Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
Yacoub A; Lyons R; Verstovsek S; Shao R; Chu DT; Agrawal A; Sivaraman S; Colucci P; Paranagama D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):461-469. PubMed ID: 33839074
[TBL] [Abstract][Full Text] [Related]
40. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
Mudireddy M; Barraco D; Hanson CA; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2017 May; 92(5):454-459. PubMed ID: 28211153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]